📰 Evaluate Efficacy News
Page 7 - Evaluate Efficacy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Evaluate Efficacy. Real-time updates on events, politics, business and more.
December 21, 2021
A recently published research article in Nature Aging by a Cleveland Clinic Genomic Medicine Institute (GMI) research team, led by Feixiong Cheng, Ph.D., entitled "Endophenotype-based in silico network
December 14, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for...
December 14, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for...
December 8, 2021
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic
December 8, 2021
/PRNewswire/ -- Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine...
December 8, 2021
/PRNewswire/ -- Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine...
December 3, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the...
December 3, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an update to the U.S. Prescribing Information and Medication Guide for RINVOQ® (upadacitinib) for the...
November 1, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
November 1, 2021
ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...